The European Commission approved up to €403 million ($472 million) in funding to support development of innovations in ...

Current treatments for Alzheimer’s disease have limited effects. While they can slow cognitive decline or alleviate symptoms, ...

After a tough few weeks for Sarepta Therapeutics Inc., the EMA dealt another blow on July 25, announcing it will not be approving the Duchenne muscular dystrophy gene therapy Elevidys (delandistrogene ...

Opus Genetics Inc. has entered a strategic partnership with the Global RDH12 Alliance to advance Opus’ gene therapy program for patients with vision loss due to retinol dehydrogenase 12 (RDH12) gene ...